Literature DB >> 25744846

[Elevated levels of dendritic cell-correlated miRNAs in ascites and sera of patients with ovarian cancer].

Xiaoqing Wu1, Xiaogai Zhi1, Mengna Liu1, Jingyan Xie1, Shuli Zhao1.   

Abstract

OBJECTIVE: To investigate the relationship between the clinical characteristics of ovarian cancer and the levels of miRNAs which could regulate the differentiation of dendritic cells, and assess its value in estimating the immune state and prognosis of ovarian cancer patients.
METHODS: Real-time quantitative PCR was used to determine the levels of miRNAs in ascites and sera of 39 cases of ovarian cancer and in the sera of 20 healthy women.
RESULTS: The levels of miR-21, miR-222 and miR-142-3p in sera of ovarian cancer patients were significantly higher than those of the healthy. The expression of miR-21 was higher in the advanced stages (III and IV) than in the earlier stages (I and II ), whereas the level of serum miR-142-3p was lower in high pathological grade than in low grade. The levels of miR-21 and miR-222 in the ascites were higher than those in the peripheral blood.
CONCLUSION: The increased expressions of miR-21, miR-222 and miR-142-3p in the ascites and sera of ovarian cancer patients might be correlated with the clinical pathological grading of the patients.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25744846

Source DB:  PubMed          Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi        ISSN: 1007-8738


  2 in total

1.  Comparative Gene Expression Analysis of Lymphocytes Treated with Exosomes Derived from Ovarian Cancer and Ovarian Cysts.

Authors:  Yujuan Li; Yang Yang; Aiwei Xiong; Xiaoqin Wu; Jingyan Xie; Suping Han; Shuli Zhao
Journal:  Front Immunol       Date:  2017-06-01       Impact factor: 7.561

2.  MicroRNA-142-3p inhibits cell proliferation and chemoresistance in ovarian cancer via targeting sirtuin 1.

Authors:  Jianlian Gao; Nan Wu; Xiaohong Liu; Yuechong Xia; Ying Chen; Shaoru Li; Zhijian Deng
Journal:  Exp Ther Med       Date:  2018-04-27       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.